ICE is a combination chemotherapy regimen employing three drugs: ifosfamide (trade name: Ifex), carboplatin (trade name: Paraplatin), and etoposide (trade names: VP-16, VePesid). This regimen is commonly used to treat primary progressive and poor-risk recurrent lymphomas.[1]
In the last few years, it has become more common to include the drug rituximab alongside the ICE protocol, a regimen commonly referred to as R-ICE. Rituximab is a monoclonal antibody which binds to and helps destroy B cells.[2]